Table 1.
Prevalence of sex-stratified clinical and symptomatic knee osteoarthritis.
| Author | Country | Population | Age (years) | OA type | Diagnosis method | OA prevalence (%) | |||
|---|---|---|---|---|---|---|---|---|---|
| Male (%) |
Female (%) |
Mean (Range/SD) | Total | Male | Female | ||||
| Prieto-Alhambra et al., 2014 (22) | Spain | 1,529,595 (46.8) | 1,737,231 (53.2) | 67.3 (SD11.0) | Clinical knee | ICD code | 96,222 (2.9) | 34,243 (2.2) | 61,979 (3.6) |
| Swain et al., 2022 (23) | UK | 1,690,618 | Inclusion ≥20 (NA) | Clinical knee | Coded diagnosis (2017) | NA (2.3) | NA (2.5) | NA (3.2) | |
| Li et al., 2020 (24) | China | 74,908 | Inclusion ≥15 (NA) | Symptomatic knee | Assorted | 10,937 (14.6) | NA (10.9) | NA (19.1) | |
| Mork et al., 2012 (28) | Norway | 14,766 (49.3) | 15,191 (50.7) | 43.79 (SD 14.0) | Symptomatic knee | Questionnaire | 351 (1.2) | 132 (0.9) | 219 (1.4) |
| Hawker et al., 2000 (20) | Canada | 11,930 (42.0) | 16,521 (58.0) | M: 69.4 (SD 8.7) F: 70.9 (SD 9.6) |
Symptomatic hip and knee | WOMAC score ≥39 | 1,325 (4.7) | 332 (2.8) | 993 (6.0) |
| Tang et al., 2015 (35) | China | 8,367 (48.8) | 8,761 (51.2) | M: 59.8 (SD 0.2) F: 59.8 (0.2) |
Symptomatic knee | Questionnaire (CHARLS) | 1,360 (8.1) | 478 (5.7) | 902 (10.3) |
| Park et al., 2017 (34) | Korea | 3,830 (42.7) | 5,146 (57.3) | Inclusion ≥50 (NA) | Symptomatic knee | Questionnaire | 754 (8.4) | 260 (6.8) | 494 (9.6) |
| Welling et al., 2017 (40) | Finland | 3,904 (47.3) | 4,344 (52.7) | Inclusion ≥46 (NA) | Clinical knee | ICD code | 202 (2.5) | 98 (2.5) | 104 (2.4) |
| Zhang et al., 2016 (43) | China | 3,609 (50.7) | 3,517 (49.4) | 43.9 (SD 16.6) | Clinical knee | ACR criteria | 983 (13.8) | 446 (12.4) | 537 (15.3) |
| Haq et al., 2005 (36) | Bangladesh | 2,582 (50.0) | 2,578 (50.0) | Inclusion ≥15 (NA) | Symptomatic knee | Questionnaire and examination | 451 (8.7) | 190 (7.4) | 261 (10.1) |
| Plotnikoff et al., 2015 (31) | Canada | 1,542 (32.6) | 3,189 (67.4) | 52.5 (SD 16.5) | Symptomatic knee | Questionnaire | 352 (7.4) | 146 (9.5) | 206 (6.5) |
| Ji et al., 2023 (37) | China | 1,950 (49.7) | 1,974 (50.3) | 58.44 (SD 9.2) | Symptomatic knee | ACR criteria | 404 (10.3) | 126 (6.5) | 278 (14.1) |
| Tukker et al., 2009 (25) | The Netherlands | 1,640 (44.8) | 2,024 (55.2) | 54.6 (NA) | Symptomatic knee | Questionnaire | 547 (14.9) | 213 (13.0) | 334 (16.5) |
| Picavet et al., 2003 (41) | The Netherlands | 1,641 (44.8) | 2,023 (55.2) | Inclusion ≥25 (NA) | Self-reported knee | Questionnaire | 441 (12.0) | 166 (10.1) | 275 (13.6) |
| Grotle et al., 2008 (33) | Norway | 1,480 (45.3) | 1,786 (54.7) | 60.44 (IQR 21) | Symptomatic knee | Questionnaire | 233 (7.1) | 92 (6.2) | 141 (7.9) |
| Felson et al., 1987 (39) | USA | 587 (41.4) | 831 (58.6) | 73 (Range 63-94) | Symptomatic knee | X-rays and questionnaire | 135 (9.5) | 40 (6.8) | 95 (11.4) |
| Carmona et al., 2001 (30) | Spain | 1,014 (46.3) | 1,178 (53.7) | Inclusion ≥20 (NA) | Symptomatic knee | ACR criteria | 223 (10.2) | 58 (5.7) | 165 (14.0) |
| Macias-Hernandez SI et al., 2020 (32) | Mexico | 80 (39.2) | 124 (60.8) | 57.4 (SD 10.9) | Clinical knee | Questionnaire | 40 (19.6) | 10 (12.5) | 30 (24.2) |
ACR, American College of Rheumatology; ICD, International Classification of Diseases; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; UK, United Kingdom; USA, United States of America.